{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:50Z","timestamp":1777934510721,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Osimertinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor. Elevated serum creatine kinase level is an uncommon adverse event associated with osimertinib treatment for lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>We report a previously healthy 56-year-old woman who developed elevated serum creatine kinase levels during osimertinib monotherapy for epidermal growth factor receptor mutation-positive lung adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>During treatment, she experienced leg cramps and her serum creatine kinase levels increased, peaking at 989 U\/l. Further investigation revealed no evidence of cardiotoxicity or myositis; thus, osimertinib-induced myopathy was assumed to be the cause of her elevated serum creatine kinase levels. We successfully managed both lung cancer and osimertinib-induced myopathy using 1-week pauses of osimertinib therapy without dose reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Short-term suspension of osimertinib without dose reduction may be a reasonable option for osimertinib-induced myopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211042271","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T15:31:09Z","timestamp":1633361469000},"page":"489-494","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Elevated serum creatine kinase levels due to osimertinib: A case report and review of the literature"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2053-8858","authenticated-orcid":false,"given":"Hiroshi","family":"Sugimoto","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kobe Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kobe Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"bibr1-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"bibr2-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"bibr3-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"bibr4-10781552211042271","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.83a.14120"},{"key":"bibr5-10781552211042271","first-page":"172","volume":"1","author":"Anand K","year":"2019","journal-title":"Cardio Oncol"},{"key":"bibr6-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2007.08.010"},{"key":"bibr8-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071770"},{"key":"bibr9-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.014"},{"key":"bibr10-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100254"},{"key":"bibr11-10781552211042271","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2008.n.036"},{"key":"bibr12-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1177\/030089161109700327"},{"key":"bibr13-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2885-6"},{"key":"bibr14-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"bibr15-10781552211042271","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411817"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211042271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211042271","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211042271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:30Z","timestamp":1777688730000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211042271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/10781552211042271"],"URL":"https:\/\/doi.org\/10.1177\/10781552211042271","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]}}}